CG MedTech Co

CG MedTech Co Net Debt / EBITDA

The Net Debt to EBITDA of CG MedTech Co (056090.KQ) as of Oct 21, 2026 is 0.23. In the previous year, Net Debt to EBITDA was -4.40 — a change of -105.12% (higher).

Net Debt / EBITDA

0.23

YoY

-105.12%

Last updated:

Net Debt to EBITDA of CG MedTech Co is 2025 0.23 . Net Debt to EBITDA of CG MedTech Co was 2024 -4.40 . It decreases by -105.12% higher compared to the previous year.

The CG MedTech Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
1.81 KRW
Jan 1, 2018
-0.89 KRW
Jan 1, 2019
-33.05 KRW
Jan 1, 2020
-1.38 KRW
Jan 1, 2021
-2.32 KRW
Jan 1, 2022
52.68 KRW
Jan 1, 2024
-4.40 KRW
Jan 1, 2025
0.23 KRW
The CG MedTech Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.23-105.12%
-4.40-108.36%
52.68-2,371.91%
-2.32+68.64%
-1.38-95.84%
-33.05+3,603.12%
-0.89-149.43%
1.81-79.04%
8.61-224.42%
-6.92-210.87%
6.24-28.45%
8.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CG MedTech Co Stock analysis

What does CG MedTech Co do? CG MedTech Co Ltd generates revenue through two primary business segments. The Medical Device Business segment produces and sells spinal fixation devices, micro-invasive medical devices for back pain treatment, fracture treatment devices, and bioabsorbable alloy implants. These products are sold to healthcare providers and hospitals within the orthopaedic surgical market. The Electric Energy Business segment manufactures and markets electricity meters and integrated calorimeters, targeting utility companies and energy management sectors. Both segments operate under the company's established brand presence in their respective industries. The company's revenue streams are derived from direct sales to end-users in the medical and energy sectors. Orthopaedic surgical implants and devices are purchased by hospitals and clinics specializing in orthopaedic care, while electricity meters and calorimeters are bought by utility providers for infrastructure deployment. The firm's product portfolio is designed to meet specific technical requirements within these specialized markets. CG MedTech Co Ltd's business model focuses on manufacturing high-precision medical devices and energy measurement equipment. The Medical Device Business segment serves the healthcare industry with products for spinal and fracture treatments, while the Electric Energy Business segment supports energy management through metering solutions. This dual-segment approach allows the company to serve two distinct but complementary industrial sectors. CG MedTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CG MedTech Co stock

Net Debt to EBITDA of CG MedTech Co is 0.23 in 2025.

Net Debt to EBITDA of CG MedTech Co changed from -4.40 to 0.23, representing a -105.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA CG MedTech Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's CG MedTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CG MedTech Co

All Key Metrics — CG MedTech Co